Restricted accessResearch articleFirst published online 2015-03
rs7903146 Polymorphism at Transcription Factor 7 Like 2 Gene Is Associated with Total Cholesterol and Lipoprotein Profile in HIV/Hepatitis C Virus-Coinfected Patients
Transcription factor 7 like 2 (TCF7L2) rs7903146 polymorphism has been associated with metabolic disturbance and cardiovascular disease. The aim of this study was to analyze the association between TCF7L2 rs7903146 polymorphism and potential disturbances on the lipid profile in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. We performed a cross-sectional study on 263 HIV/HVC-coinfected patients. TCF7L2 polymorphism was genotyped by GoldenGate assay. The analysis was performed by linear and logistic regression under a dominant model of inheritance. The variables analyzed were total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), non-HDL-C, and triglycerides. Patients harboring the rs7903146 TT/TC genotype showed a diminished concentration of TC (p=0.003), LDL-C (p=0.004), HDL-C (p=0.012), and non-HDL-C (p=0.013), a lower percentage of TC≥200 mg/dl (p=0.038), and a higher percentage of HDL≤40 mg/dl (p=0.023). In addition, we observed that rs7903146 was differently related to fasting serum lipid levels according to the HCV-genotype (HCV-GT). With regard to HCV-GT1 patients, the rs7903146 TT/TC genotype was associated with lower levels of HDL-C [adjusted arithmetic mean ratio (aAMR)=0.91; p=0.049] and an elevated percentage of patients with HDL-C≤40 mg/dl [adjusted odds ratio (aOR)=3.26; p=0.003]. For HCV-GT3 patients, the rs7903146 TT/TC genotype was associated with lower serum values of TC (aAMR=0.81; p=0.037), LDL-C (aAMR=0.67; p=0.001), and non-HDL-C (aAMR=0.75; p=0.002) and a reduced percentage of TC≥200 mg/dl (aOR=0.089; p=0.037). In conclusion, the TCF7L2 rs7903146 TT/TC genotype was associated with lower levels of TC, LDL, and HDL in HCV-GT3 patients, and lower levels of HDL-C in HCV-GT1 patients, suggesting a role in cardiovascular disease and a potential use as a biomarker in HIV/HCV-coinfected patients.
Get full access to this article
View all access options for this article.
References
1.
Collaboration ATC: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis, 2010; 50(10):1387–1396.
2.
CoreyKE, KaneE, MunroeC, et al.: Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology, 2009; 50(4):1030–1037.
3.
FreibergMS, ChangCC, KullerLH, et al.: HIV infection and the risk of acute myocardial infarction. JAMA Intern Med, 2013; 173(8):614–622.
4.
BedimoR, WestfallAO, MugaveroM, et al.: Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med, 2010; 11(7):462–468.
5.
SamarasK: Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother, 2008; 61(2):238–245.
6.
FeeneyER: HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J, 2011; 5:49–63.
7.
YounossiZM, StepanovaM, NaderF, et al.: Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther, 2013; 37(6):647–652.
8.
NegroF and SanyalAJ: Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data. Liver Int, 2009; 29(Suppl 2):26–37.
9.
MaciasJ, BerenguerJ, JaponMA, et al.: Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology, 2009; 50(4):1056–1063.
10.
Lopez-DieguezM, MontesML, Pascual-ParejaJF, et al.: The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS, 2011; 25(7):899–904.
11.
CraneHM, GrunfeldC, WilligJH, et al.: Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS, 2011; 25(2):185–195.
12.
BuchaczK, WeidlePJ, MooreD, et al.: Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr, 2008; 47(3):304–311.
13.
RiddlerSA, SmitE, ColeSR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA, 2003; 289(22):2978–2982.
14.
MontesML, PulidoF, BarrosC, et al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother, 2005; 55(5):800–804.
15.
EstradaV and PortillaJ: Dyslipidemia related to antiretroviral therapy. AIDS Rev, 2011; 13(1):49–56.
16.
Evaluating and managing cardiovascular disease risk factors in HIV-infected patients. Topics HIV Med, 2010; 18(5):164–168.
17.
Friis-MollerN, SabinCA, WeberR, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 2003; 349(21):1993–2003.
18.
Friis-MollerN, ReissP, SabinCA, et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007; 356(17):1723–1735.
19.
WuY, WaiteLL, JacksonAU, et al.: Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet, 2013; 9(3):e1003379.
20.
Pineda-TenorD, BerenguerJ, Garcia-BroncanoP, et al.: Association of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patients. Eur J Clin Invest, 2014; 44(5):453–462.
21.
Pineda-TenorD, MicheloudD, BerenguerJ, et al.: SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients. AIDS, 2014; 28(9):1325–1332.
22.
JinT: The WNT signalling pathway and diabetes mellitus. Diabetologia, 2008; 51(10):1771–1780.
23.
PovelCM, BoerJM, ReilingE, et al.: Genetic variants and the metabolic syndrome: A systematic review. Obes Rev, 2011; 12(11):952–967.
24.
PengS, ZhuY, LuB, et al.: TCF7L2 gene polymorphisms and type 2 diabetes risk: A comprehensive and updated meta-analysis involving 121,174 subjects. Mutagenesis, 2013; 28(1):25–37.
25.
Perez-MartinezP, Perez-CaballeroAI, Garcia-RiosA, et al.: Effects of rs7903146 variation in the Tcf7l2 gene in the lipid metabolism of three different populations. PloS One, 2012; 7(8):e43390.
26.
BoccardiV, AmbrosinoI, PapaM, et al.: Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity. Eur J Hum Genet, 2010; 18(12):1333–1338.
27.
BonnetF, RousselR, NataliA, et al.: Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. Diabetologia, 2013; 56(4):2414–2423.
28.
Panel de expertos de Gesida Plan Nacional sobre el Sida y Asociación Española para el Estudio del Hígado. [Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus.]. Enfermed Infeccios Microbiol Clin, 2010; 28(1):31e1.
29.
Panel de expertos de Gesida y Plan Nacional sobre el Sida. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009).]. Enfermed Infeccios Microbiol Clin, 2009; 27(4):222–235
30.
ThorpeLE, OuelletLJ, HershowR, et al.: Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol, 2002; 155(7):645–653.
31.
FriedewaldWT, LevyRI, and FredricksonDS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18(6):499–502.
32.
Martinez-HervasS, RealJT, PriegoMA, et al.: Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population. Int J Clin Pract, 2013; 67(1):81–88.
33.
MatthewsDR, HoskerJP, RudenskiAS, et al.: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28(7):412–419.
34.
JacobsWH and GoldbergSB: Statement on outpatient percutaneous liver biopsy. Digest Dis Sci, 1989; 34(3):322–323.
35.
ResinoS, SeoaneJA, BellonJM, et al.: An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. J Infect, 2011; 62(1):77–86.
36.
BedossaP and PoynardT: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996; 24(2):289–293.
37.
Huertas-VazquezA, PlaisierC, Weissglas-VolkovD, et al.: TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia, 2008; 51(1):62–69.
38.
MussoG, GambinoR, PaciniG, et al.: Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology, 2009; 49(2):426–435.
39.
SousaAG, MarquezineGF, LemosPA, et al.: TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PloS One, 2009; 4(11):e7697.
40.
MelzerD, MurrayA, HurstAJ, et al.: Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med, 2006; 4:34.
41.
CauchiS, MeyreD, ChoquetH, et al.: TCF7L2 variation predicts hyperglycemia incidence in a French general population: The data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes, 2006; 55(11):3189–3192.
42.
KimberCH, DoneyAS, PearsonER, et al.: TCF7L2 in the Go-DARTS study: Evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia, 2007; 50(6):1186–1191.
43.
LoriaP, MarchesiniG, NascimbeniF, et al.: Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014; 232(1):99–109.
44.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285(19):2486–2497.
45.
GrunfeldC: Dyslipidemia and its treatment in HIV infection. Top HIV Med, 2010; 18(3):112–118.
46.
DaiCY, YehML, HuangCF, et al.: Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol, 2013; [Epub ahead of print]; DOI: 10.1111/jgh.12313.
47.
Vespasiani-GentilucciU, GalloP, De VincentisA, et al.: Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol, 2014; 20(11):2825–2838.
48.
KotlerDP: Hepatitis C, human immunodeficiency virus and metabolic syndrome: Interactions. Liver Int, 2009; 29(Suppl 2):38–46.
49.
EslamM, KawaguchiT, Del CampoJA, et al.: Use of HOMA-IR in hepatitis C. J Viral Hepat, 2011; 18(10):675–684.
50.
NorrisJM and RichSS: Genetics of glucose homeostasis: Implications for insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol, 2012; 32(9):2091–2096.
51.
GrantSF, ThorleifssonG, ReynisdottirI, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet, 2006; 38(3):320–323.
52.
RuchatSM, ElksCE, LoosRJ, et al.: Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta Diabetol, 2009; 46(3):217–226.
53.
BonettiS, TrombettaM, MalerbaG, et al.: Variants and haplotypes of TCF7L2 are associated with beta-cell function in patients with newly diagnosed type 2 diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1. J Clin Endocrinol Metab, 2011; 96(2):E389–393.
54.
StolermanES, ManningAK, McAteerJB, et al.: TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia, 2009; 52(4):614–620.
55.
CauchiS, El AchhabY, ChoquetH, et al.: TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: A global meta-analysis. J Mol Med (Berl), 2007; 85(7):777–782.
56.
LuoY, WangH, HanX, et al.: Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. Diabetes Res Clin Pract, 2009; 85(2):139–146.
57.
TongY, LinY, ZhangY, et al.: Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: A large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet, 2009; 10:15.
58.
MarziC, HuthC, KolzM, et al.: Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res, 2007; 39(1):46–52.
59.
FlorezJC, JablonskiKA, BayleyN, et al.: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med, 2006; 355(3):241–250.
60.
HelgasonA, PalssonS, ThorleifssonG, et al.: Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet, 2007; 39(2):218–225.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
